肯尼亚每年两次批准在感染增加的情况下注射艾滋病毒预防。 Kenya approves twice-yearly HIV prevention injectable, amid rising infections.

肯尼亚批准了Lenacapavir,这是每年两次注射的艾滋病毒预防药物,成为第一批这样做的非洲国家之一。 Kenya has approved lenacapavir, a twice-yearly injectable HIV prevention drug, becoming one of the first African nations to do so. 这一行动是在严格审查该药物的安全性和有效性之后进行的,并且符合世界卫生组织的指导。 The move follows a rigorous review of the drug’s safety and effectiveness and aligns with World Health Organization guidance. 长效选择旨在改善对高风险人群的遵守。 The long-acting option aims to improve adherence for high-risk populations. 根据国家卫生数据,2024年新的艾滋病毒感染病例上升19%,达到19 991人,因此作出这一决定。 The decision comes as new HIV infections rose 19% in 2024, reaching 19,991, according to national health data.